Gene therapy for erectile dysfunction: What is the future?

Current Urology Reports

Volumn 11, Issue 6, 2010, Pages 421-426

  Melman, Arnold ^a   Davies, Kelvin ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Corpora cavernous; Erectile dysfunction; Gene transfer; Naked DNA, Overactive bladder; Phase I trial; Plasmid; Smooth muscle

Indexed keywords

LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNIT; NAKED DNA; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLASMID DNA; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL;

CLINICAL TRIAL; DRUG SAFETY; ERECTILE DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; GENE TRANSFER; HUMAN; NONHUMAN; NONVIRAL GENE THERAPY; REVIEW;

ANIMALS; ERECTILE DYSFUNCTION; FORECASTING; GENE THERAPY; HUMANS; MALE;

EID: 77958085764     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-010-0145-1     Document Type: Review

References (15)

1. P Saraswat RR Soni A Bhandari BP Nagori 2009 DNA as therapeutics; an update Indian J Pharm Sci 71 488 498 1:STN:280:DC%2BC3czmsVektA%3D%3D 10.4103/0250-474X.58169 20502565
2. TA Ratko JP Cummings J Blebea KA Matuszewski 2003 Clinical gene therapy for nonmalignant disease Am J Med 115 560 569 1:CAS:528:DC%2BD3sXos1Omtrs%3D 10.1016/S0002-9343(03)00447-9 14599636 (Pubitemid 37352803)
3. CC Shieh M Coghlan JP Sullivan M Gopalakrishnan 2000 Potassium channels: molecular defects, diseases, and therapeutic opportunities Pharmacol Rev 52 557 594 1:CAS:528:DC%2BD3MXislWksA%3D%3D 11121510
4. VP Korovkina SK England 2002 Molecular diversity of vascular potassium channel isoforms Clin Exp Pharmacol Physiol 29 317 323 1:CAS:528: DC%2BD38XisVKmsL8%3D 10.1046/j.1440-1681.2002.03651.x 11985543 (Pubitemid 34227067)
5. VP Korovkina SK England 2002 Detection and implications of potassium channel alterations Vascul Pharmacol 38 3 12 1:CAS:528:DC%2BD38Xns1ersLY%3D 10.1016/S1537-1891(02)00121-0 12378820 (Pubitemid 36398285)
6. KP Davies W Zhao M Tar, et al. 2007 Diabetes-induced changes in the alternative splicing of the slo gene in corporal tissue Eur Urol 52 1229 1237 1:CAS:528:DC%2BD2sXht1Wgu77P 10.1016/j.eururo.2006.11.028 17150299 (Pubitemid 47332014)
7. KS Thorneloe AL Meredith AM Knorn, et al. 2005 Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder Am J Physiol Renal Physiol 289 F604 F610 1:CAS:528:DC%2BD2MXhtVWktrfL 10.1152/ajprenal.00060.2005 15827347 (Pubitemid 41208476)
8. ME Werner P Zvara AL Meredith, et al. 2005 Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel J Physiol 567 545 556 1:CAS:528:DC%2BD2MXhtVaqur%2FN 10.1113/jphysiol.2005.093823 16020453 (Pubitemid 41301050)
9. A Melman KP Davies 2009 Gene therapy in the management of erectile dysfunction (ED): past, present, and future Scientific World Journal 9 846 854 1:CAS:528:DC%2BC3cXhsVSjsb4%3D 20333343 This is a good complementary review of gene transfer for therapy for erectile dysfunction
10. A Melman N Bar-Chama A McCullough, et al. 2006 hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial Hum Gene Ther 17 1165 1176 1:CAS:528:DC%2BD28XhtlGktLfJ 10.1089/hum.2006.17.1165 17134370 (Pubitemid 44975134)
11. S Lehrman 1999 Virus treatment questioned after gene therapy death Nature 401 517 518 1:CAS:528:DyaK1MXmvFCns7k%3D 10.1038/43977 10524611
12. •• Christ GJ, Andersson KE, Williams K, et al.: Smooth-Muscle-Specific Gene Transfer with the Human Maxi-K Channel Improves Erectile Function and Enhances Sexual Behavior in Atherosclerotic Cynomolgus Monkeys. Eur Urol 2008 Dec 25 (Epub ahead of print). This report demonstrates the versatility of plasmid-based therapy. In this case, the hSlo gene was used in a plasmid backbone with a smooth muscle-activated-only promoter. In addition, it demonstrated that the product could correct erectile dysfunction that was caused by atherosclerosis in a primate model.
13. R Rosen I Goldstein XY Huang, et al. 2007 The Treatment Satisfaction Scale (TSS) is a sensitive measure of treatment effectiveness for both patients and partners: results of a randomized controlled trial with vardenafil J Sex Med 4 1009 1021 1:CAS:528:DC%2BD2sXptFKjtr4%3D 10.1111/j.1743-6109.2007.00527.x 17627746 (Pubitemid 47079634)
14. A Melman L Rojas G Christ 2009 Gene transfer for erectile dysfunction: will this novel therapy be accepted by urologists? Curr Opin Urol 19 595 600 10.1097/MOU.0b013e3283314985 19741539 This manuscript reports the results of a web-based survey to determine if clinical urologists would be willing to utilize gene transfer in their practice
15. H Porst Y Vardi E Akkus, et al. 2010 Standards for clinical trials in male sexual dysfunctions J Sex Med 7 414 444 1:CAS:528:DC%2BC3cXitFGjtr0%3D 10.1111/j.1743-6109.2009.01623.x 20092447 This wonderful review forms a basis of understanding for the basic requirements of clinical trials